共查询到19条相似文献,搜索用时 178 毫秒
1.
血管紧张素转换酶2(angiotensin—converting enzyme 2,ACE2)是新发现的与血管紧张素转换酶(ACE)相关的羧肽酶,在肾素-血管紧张素系统(rennin-angiotensin system,RAS)中ACE2可以使AngⅡ转换为Ang1-7,从而产生与血管紧张素Ⅱ相反的效应,同时ACE2还可使Ang I转换为Ang1-9。研究发现:ACE2与高血压、SARS以及肾脏、生殖等系统的疾病有着密切的关系。 相似文献
2.
2019冠状病毒病(coronavirus disease 2019,COVID-19)的病原学和临床表现多有报道。该病在病原学和临床表现上与发生在2003年的严重急性呼吸综合征(severe acute respiratory syndrome, SARS)有诸多相似性。本文通过对比两者异同,尝试从其共同受体血管紧张素转换酶2(angiotensin converting enzyme 2,ACE2)角度,提出并探讨患者肠道菌群可能参与其致病的潜在机制,旨在为深入探索新型冠状病毒,即严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)的致病机制及加速研发重症肺炎预测指标提供一种可能的新思路。 相似文献
3.
肾素-血管紧张素系统的新调节分子:ACE2 总被引:2,自引:0,他引:2
血管紧张素转化酶(angiotensin—converting enzyme,ACE)为含锌的金属蛋白酶,是肾素-血管紧张素系统(renin—angiotensin system,RAS)重要的调节分子。血管紧张素转化酶2(angiotensin—con—verting enzyme2,ACE2)是迄今发现的唯一的ACE同系物(homologue),它主要分布于睾丸、肾脏和心脏。ACE2可水解血管紧张素Ⅰ(angiotensinⅠ,AngⅠ)和血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)羧基端的1个氨基酸残基,分别形成Ang1-9和有血管舒张作用的Ang1-7。ACE2的生理病理作用还不甚明了,传统的ACE抑制剂不能抑制ACE2的活性。ACE2在心血管、肾脏系统的作用可能与ACE相反.与ACE共同调节心脏、肾脏等脏器的正常功能。 相似文献
4.
自新型冠状病毒肺炎暴发以来,中国已累计超过8万例患者。随着对其病毒结构和感染机制的深入研究,研究者们发现血管紧张素转换酶(Angiotensin converting enzyme,ACE)2是新型冠状病毒(SARS-CoV-2)的受体。根据既往的研究,ACE2是肾素血管紧张素系统(Renin angiotensin system,RAS)的关键酶之一,与其同源物ACE在该系统中起协同调节作用,同时,其生理调节功能也广泛作用于心血管、肾脏、肝脏、肠道等。疫情暴发后,人们急于了解SARS-CoV-2的溯源、中间宿主、流行病学分析和治疗的靶点,ACE2身份的转变使其成为研究的热点之一。本文就目前ACE2在SARS-CoV-2和心血管等领域的研究进展进行简要综述,以期为SARS-CoV-2的溯源、跨物种传播、流行病学分析以及抗病毒药物靶点研究提供参考依据。 相似文献
5.
6.
血管紧张素转换酶的结构功能及相关抑制剂 总被引:2,自引:0,他引:2
血管紧张素转化酶(angiotensin converting enzyme, ACE, EC 3.4.15.1)是一种位于细胞膜上, 依赖锌离子的羧二肽酶, 催化水解十肽血管紧张素I羧基末端两个氨基酸, 生成具有血管收缩作用的八肽血管紧张素II。ACE在血压调节系统renin - angiotensin system (RAS系统)中具有重要作用, 从ACE的结构功能、基因多态性及其抑制剂等方面进行了详细综述。发现体细胞ACE两个活性中心催化血管紧张素I和缓激肽的机制不同, 因此以体细胞ACE单个活性中心为靶点的研究, 将会为研制开发副作用更少, 安全性更高的ACE抑制剂提供新的途径。 相似文献
7.
由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的病毒性肺炎已经扩散到全球200多个国家和地区,导致了数十万人死亡。2019冠状病毒病(coronavirus disease 19,COVID-19)的流行病学、致病机制和临床治疗方法成为各国政府以及科研界亟待研究解决的重大问题。本文对SARS-CoV-2的病原学特征及COVID-19的发病机制、病理学研究进展进行综述,重点评述病毒受体人血管紧张素转换酶Ⅱ (human angiotensin-converting enzyme 2,ACE2)与病毒致病机制的相关性,为后续研究与防治提供参考。 相似文献
8.
《微生物学免疫学进展》2020,(4)
新型冠状病毒(severe acute respiratory syndrome coronavirus-2, SARS-CoV-2)是一种可引起人新型冠状病毒肺炎(novel coronavirus pneumonia, NCP;亦称为COVID-19)的新发呼吸道病原体,与中东呼吸综合征冠状病毒(Middle East respiratory syndrome coronavirus, MERS-CoV)和严重急性呼吸综合征冠状病毒(severe acute respiratory syndrome coronavirus, SARS-CoV)同属β-冠状病毒,其受体与SARS-CoV的受体相同,均利用血管紧张素转化酶2(angiotensin-converting enzyme 2, ACE2)受体入侵人体细胞。SARS-CoV-2主要通过呼吸系统和消化系统感染,具有较高的传染性和致死率。目前,新冠病毒引起的肺炎已在全球范围内大规模蔓延,接种疫苗是根除病毒性传染病最有效的方法,国内外各大科研机构已快速展开COVID-19疫苗的研制工作,这是有效控制疫情的重点和难点。现就新冠病毒的致病机理、感染途径及疫苗研发作一综述,旨在为相关研究人员提供参考。 相似文献
9.
10.
由严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus-2,SARS-CoV-2)引起的疾病被命名为新型冠状病毒肺炎(coronavirus disease 2019,COVID-19),是一种具有强传染性、高易感性、长潜伏期的传染病。病毒刺突蛋白受体结合结构域(receptor binding domain,RBD)和细胞血管紧张素转换酶2(angiotensin-converting enzyme 2,ACE2)之间的相互作用使得SARS-CoV-2顺利进入细胞。本文对SARS-CoV-2与ACE2的相关作用机制进行了简单概述,对目前针对SARS-CoV-2中和单克隆抗体、纳米抗体的最新研究进展进行了总结,探讨了新冠肺炎的发展过程和抗体药物的研究方向,以期为包括新冠肺炎在内的新发、突发传染病中和抗体药物的研发提供参考。 相似文献
11.
Hofmann H Geier M Marzi A Krumbiegel M Peipp M Fey GH Gramberg T Pöhlmann S 《Biochemical and biophysical research communications》2004,319(4):1216-1221
The angiotensin converting enzyme 2 (ACE2) has been identified as a receptor for the severe acute respiratory syndrome associated coronavirus (SARS-CoV). Here we show that ACE2 expression on cell lines correlates with susceptibility to SARS-CoV S-driven infection, suggesting that ACE2 is a major receptor for SARS-CoV. The soluble ectodomain of ACE2 specifically abrogated S-mediated infection and might therefore be exploited for the generation of inhibitors. Deletion of a major portion of the cytoplasmic domain of ACE2 had no effect on S-driven infection, indicating that this domain is not important for receptor function. Our results point to a central role of ACE2 in SARS-CoV infection and suggest a minor contribution of the cytoplasmic domain to receptor function. 相似文献
12.
目的:探讨汉族人群中血管紧张素转换酶抑制剂(ACEI)所致咳嗽与血管紧张素转换酶(ACE)基因及缓激肽β2受体(BDK-RB2)基因多态性的关系。方法:应用聚合酶链反应(PCR)方法。检测汉族人群中151例由于服用ACEI引起的咳嗽患者及151例未发生咳嗽的患者的ACEI/D及BDKRB2C/T的多态性,并采用紫外法检测ACE活性。结果:发现ACE基因分布在咳嗽组中II型为47.0%,ID型为42.4%,DD型为10.6%;无咳嗽组分别为39.7%、47.0%、13.3%,两组相比其差异具有统计学意义(P〈0.01);BDKRB2基因分布在咳嗽组中CC型为21.3%,CT型为50.0%,TT型为28.7%,无咳嗽组分别为22.5%、47.7%、29.8%。两组相比其差异无统计学意义(P〉0.05);咳嗽组ACE活性水平为[(28.3±10.1)U/L]明显低于无咳嗽组[(40.2±9.4)U/L],两组相比其差异具有统计学意义(P〈0.01)。结论:汉族人群中ACEI所致咳嗽与ACE基因多态性及血清ACE水平有关,BDKRB2C/T与咳嗽间未发现有统计学意义的关联。 相似文献
13.
近年来,糖尿病肺部病变越来越受到关注。研究发现糖尿病患者存在肺通气功能障碍、弥散功能障碍,易于发生肺纤维化、合
并感染等。这主要与糖尿病时炎症介质的参与,ACE 基因存在插入多态性,氧化应激损伤和抗氧化失衡等有关。目前研究发现血
管紧张素转换酶抑制剂(ACEI)/ 血管紧张素受体阻滞剂(ARB)对糖尿病肺炎、慢性阻塞性肺疾病、肺间质纤维化等肺损伤有保护
作用,这可能与ACEI具有调节免疫反应、减轻细胞因子水平、抗氧化应激损伤等机制有关。 相似文献
14.
近年来,糖尿病肺部病变越来越受到关注。研究发现糖尿病患者存在肺通气功能障碍、弥散功能障碍,易于发生肺纤维化、合并感染等。这主要与糖尿病时炎症介质的参与,ACE基因存在插入多态性,氧化应激损伤和抗氧化失衡等有关。目前研究发现血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)对糖尿病肺炎、慢性阻塞性肺疾病、肺间质纤维化等肺损伤有保护作用,这可能与ACEI具有调节免疫反应、减轻细胞因子水平、抗氧化应激损伤等机制有关。 相似文献
15.
Andujar-Sánchez M Cámara-Artigas A Jara-Pérez V 《Journal of chromatography. B, Analytical technologies in the biomedical and life sciences》2003,783(1):247-252
Angiotensin I converting enzyme (ACE) plays a major role in blood pressure regulation, catalyzing the conversion of angiotensin I to the vasoconstrictor angiotensin II. In this report we describe a two-step affinity chromatography method for preparative purification of ACE from pig lung using Concanavalin-A Sepharose 4B and affinity chromatography on Lisinopril Sepharose 6B. The same purification scheme was used to obtain Cobalt-ACE, where zinc ion located at the active site is replaced by cobalt. Cobalt-ACE visible spectrum shows a characteristic broad peak from 500 to 600 nm. The shape and maximum absorptivity of this peak changes in presence of ACE inhibitors that bind at the catalytic site. 相似文献
16.
Hang Yang Huijun Yuan Xiaohui Zhao Meng Xun Shangrui Guo Nan Wang Bing Liu Hongliang Wang 《中国病毒学》2022,37(3):380-389
The recent COVID-19 pandemic poses a global health emergency. Cellular entry of the causative agent SARS-CoV-2 is mediated by its spike protein interacting with cellular receptor-human angiotensin converting enzyme 2 (ACE2). Here, by using lentivirus based pseudotypes bearing spike protein, we demonstrated that entry of SARS-CoV-2 into host cells was dependent on clathrin-mediated endocytosis, and phosphoinositides played essential roles during this process. In addition, we showed that the intracellular domain and the catalytic activity of ACE2 were not required for efficient virus entry. Finally, we showed that the current predominant Delta variant, although with high infectivity and high syncytium formation, also entered cells through clathrin-mediated endocytosis. These results provide new insights into SARS-CoV-2 cellular entry and present proof of principle that targeting viral entry could be an effective way to treat different variant infections. 相似文献
17.
Catherine Gomez Sabine Berteina-Raboin Guillaume De Nanteuil Gérald Guillaumet 《Bioorganic & medicinal chemistry》2013,21(22):7216-7221
A series of phosphonate analogues related to perindopril and ramipril were prepared and tested to estimate their ability to inhibit angiotensin converting enzyme. These new synthesized compounds were active ACE inhibitors with a promising activity. 相似文献
18.
《Saudi Journal of Biological Sciences》2021,28(11):6465-6470
The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in coronavirus disease 2019 (COVID-19) patients has been claimed as associated with the risk of COVID-19 infection and its subsequent morbidities and mortalities. These claims were resulting from the possibility of upregulating the expression of angiotensin-converting enzyme 2 (ACE2), facilitation of SARS-CoV-2 entry, and increasing the susceptibility of infection in such treated cardiovascular patients. ACE2 and renin-angiotensin-aldosterone system (RAAS) products have a critical function in controlling the severity of lung injury, fibrosis, and failure following the initiation of the disease. This review is to clarify the mechanisms beyond the possible deleterious effects of angiotensin II (Ang II), and the potential protective role of angiotensin 1–7 (Ang 1–7) against pulmonary fibrosis, with a subsequent discussion of the latest updates on ACEIs/ARBs use and COVID-19 susceptibility in the light of these mechanisms and biochemical explanation. 相似文献
19.
Zhipeng Ke Zhenzhen Su Xinzhuang Zhang Zeyu Cao Yue Ding Liang Cao Gang Ding Zhenzhong Wang Haichun Liu Wei Xiao 《Bioorganic & medicinal chemistry letters》2017,27(16):3688-3692
Prompted by the prominent role of angiotensin converting enzyme (ACE) in hypertension, heart failures, myocardial infarction and diabetic nephropathy, we have attempted to discover novel ACE inhibitors through ligand-based virtual screening. Molecular docking method and rigorously validated model was utilized to search a natural compounds database. Finally, 36 compounds were randomly selected and subjected to in vitro ACE kinase inhibitory assay using fluorescence assays method. The results showed that three compounds (Licochalcone A, Echinatin and EGCG) have strong potential to be developed as a new class of ACE inhibitors. Further chemical modification via fragment modifications guided by structure and ligand-based computational methodologies can lead to discover better agents as potential clinical candidates. 相似文献